SYNOVICS PHARMACEUTICALS INITIATES U.S. DEVELOPMENT OF ITS THIRD GENERIC ORAL CONTROLLED-RELEASE DRUG

Synovics Pharmaceuticals, Inc., a specialty pharmaceutical company with proprietary technologies for the development of controlled-release generic and branded oral drugs, today announced that its wholly owned subsidiary, Synovics Laboratories, Inc., has initiated the process for U.S. chemical, manufacturing and control (CMC) development of its third controlled-release generic drug candidate, SNG1003. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060609005159&newsLang=en)